Cargando…
New Therapeutics to Treat Castrate-Resistant Prostate Cancer
The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patient...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678432/ https://www.ncbi.nlm.nih.gov/pubmed/23781155 http://dx.doi.org/10.1155/2013/379641 |
_version_ | 1782272850347950080 |
---|---|
author | Acar, Ömer Esen, Tarık Lack, Nathan A. |
author_facet | Acar, Ömer Esen, Tarık Lack, Nathan A. |
author_sort | Acar, Ömer |
collection | PubMed |
description | The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage prostate cancer. In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials. |
format | Online Article Text |
id | pubmed-3678432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36784322013-06-18 New Therapeutics to Treat Castrate-Resistant Prostate Cancer Acar, Ömer Esen, Tarık Lack, Nathan A. ScientificWorldJournal Review Article The effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage prostate cancer. In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials. Hindawi Publishing Corporation 2013-05-27 /pmc/articles/PMC3678432/ /pubmed/23781155 http://dx.doi.org/10.1155/2013/379641 Text en Copyright © 2013 Ömer Acar et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Acar, Ömer Esen, Tarık Lack, Nathan A. New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
title | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
title_full | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
title_fullStr | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
title_full_unstemmed | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
title_short | New Therapeutics to Treat Castrate-Resistant Prostate Cancer |
title_sort | new therapeutics to treat castrate-resistant prostate cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678432/ https://www.ncbi.nlm.nih.gov/pubmed/23781155 http://dx.doi.org/10.1155/2013/379641 |
work_keys_str_mv | AT acaromer newtherapeuticstotreatcastrateresistantprostatecancer AT esentarık newtherapeuticstotreatcastrateresistantprostatecancer AT lacknathana newtherapeuticstotreatcastrateresistantprostatecancer |